Empagliflozin: a path from glycemic control to reduced cardiovascular mortality and heart failure-related hospitalizations
In the EMPA-REG OUTCOME, CANVAS and DECLARE-TIMI 58 studies, in patients with type 2 diabetes and established cardiovascular diseases or risk factors, a decrease in the risk of cardiovascular events and development or worsening of heart failure course without an increase in hypoglycemia incidence wa...
Main Author: | N. R. Khasanov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
«FIRMA «SILICEA» LLC
2022-02-01
|
Series: | Российский кардиологический журнал |
Subjects: | |
Online Access: | https://russjcardiol.elpub.ru/jour/article/view/4807 |
Similar Items
-
Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause
by: Muhammad Shahzeb Khan, et al.
Published: (2023-01-01) -
Sodium-glucose cotransporter type 2 inhibitors in patients with heart failure with preserved ejection fraction: a systematic review and meta-analysis
by: Evgeny M. Mezhonov, et al.
Published: (2023-04-01) -
Cost-utility analysis of empagliflozin in heart failure patients with reduced and preserved ejection fraction in China
by: Yi Tang, et al.
Published: (2022-10-01) -
Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure with a Preserved Ejection Fraction: A Meta-Analysis of Randomized Controlled Trials
by: Yake Lou, et al.
Published: (2022-10-01) -
Multinational cost‐effectiveness analysis of empagliflozin for heart failure patients with ejection fraction >40%
by: Spyros Kolovos, et al.
Published: (2023-12-01)